CFLAR and neoplasm: The results of our current study with the combination of bortezomib and PCC are in agreement with a recent study reported by Tewary et al., in which the authors have demonstrated the importance of PCC in sensitizing tumor cells to induce apoptosis through c-FLIP downregulation and increase the effectiveness of other treatments including polyinosinic:polycytidylic acid (poly I:C) [13].